Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.49 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933990 | 0.90 | HIF1A (0.50) | EGLN1HIF1A | |
| SCHEMBL934174 | 0.89 | — | — | |
| SCHEMBL11934004 | 0.88 | MAPK1 (0.41) | EGLN2EGLN1EGLN3KDM4EALDH1A1 | |
| SCHEMBL933166 | 0.88 | — | — | |
| SCHEMBL934327 | 0.87 | EGLN1 (0.46) | EGLN2EGLN1EGLN3HIF1A | |
| SCHEMBL934000 | 0.86 | — | — | |
| SCHEMBL27961481 | 0.85 | — | — | |
| SCHEMBL15759105 | 0.84 | EGLN1 (0.43) | EGLN1 | |
| SCHEMBL935135 | 0.84 | KDM4E (0.48) | KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL934468 | 0.84 | EGLN2 (0.48) | EGLN2EGLN1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454249-B1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSITIONS, AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO LTD (CN) | 2018-09-19 | — | — | EP | claimed |
| US-8742138-B2 | Compounds as hypoxia mimetics, and compositions and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2014-06-03 | — | — | US | claimed |
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) | 2012-07-05 | — | — | US | claimed |
| EP-2454249-B1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSITIONS, AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO LTD (CN) | 2018-09-19 | — | — | EP | disclosed |
| US-8742138-B2 | Compounds as hypoxia mimetics, and compositions and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2014-06-03 | — | — | US | disclosed |
| US-8742138-B2 | Compounds as hypoxia mimetics, and compositions and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2014-06-03 | — | — | US | disclosed |
| US-8742138-B2 | Compounds as hypoxia mimetics, and compositions and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2014-06-03 | — | — | US | disclosed |
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) | 2012-07-05 | — | — | US | disclosed |
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) | 2012-07-05 | — | — | US | disclosed |
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) | 2012-07-05 | — | — | US | disclosed |
| EP-2454249-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSITIONS, AND USES THEREOF | Zhejiang Beta Pharma Inc. (CN) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011006355-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSITIONS, AND USES THEREOF | BEIJING BETA PHARMA INC. (CN) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | HIF1AN, HIF1A, EGLN3 | EGLN2 4/4885EGLN1 5/4885EGLN3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.